1. Home
  2. TGHL vs CALC Comparison

TGHL vs CALC Comparison

Compare TGHL & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGHL

The GrowHub Limited Class A Ordinary Shares

N/A

Current Price

$0.40

Market Cap

10.5M

Sector

Technology

ML Signal

N/A

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.65

Market Cap

9.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGHL
CALC
Founded
2020
2011
Country
Singapore
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
9.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
TGHL
CALC
Price
$0.40
$0.65
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
29.5K
197.6K
Earning Date
05-18-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.46
52 Week High
$3.80
$7.20

Technical Indicators

Market Signals
Indicator
TGHL
CALC
Relative Strength Index (RSI) 49.53 43.11
Support Level $0.33 $0.50
Resistance Level $0.38 $0.78
Average True Range (ATR) 0.03 0.06
MACD 0.01 0.03
Stochastic Oscillator 60.09 41.75

Price Performance

Historical Comparison
TGHL
CALC

About TGHL The GrowHub Limited Class A Ordinary Shares

The Growhub Ltd operates at the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, It has developed a multi-faceted approach to address industry challenges. its business currently comprises two main divisions, which are the GrowHub Platform and its product trading facilitation offering.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: